List of Phasebio Pharmaceuticals, Inc. patents

List of Phasebio Pharmaceuticals, Inc. patents

List of Kimbia patents

List of Woodstream Corporation patents

List of Georgia Tech Research Corporation patents

List of companies founded by Victor Kozlov

List of alzheimer's disease patents

Patents where

Current Assignee

Name

is

‌

Phasebio Pharmaceuticals, Inc.

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11040034 Metalloenzyme inhibitor compounds	Patent 11040034 was granted and assigned to Phasebio Pharmaceuticals, Inc. on June, 2021 by the United States Patent and Trademark Office.	‌ Phasebio Pharmaceuticals, Inc.	‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	11040034	June 22, 2021
	‌ US Patent 9700598 Modified vasoactive intestinal peptides	Patent 9700598 was granted and assigned to Phasebio Pharmaceuticals, Inc. on July, 2017 by the United States Patent and Trademark Office.	‌ Phasebio Pharmaceuticals, Inc.	‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	9700598	July 11, 2017
	‌ US Patent 11266719 Methods and compositions for treating muscle disease and disorders	Patent 11266719 was granted and assigned to Phasebio Pharmaceuticals, Inc. on March, 2022 by the United States Patent and Trademark Office.	‌ Phasebio Pharmaceuticals, Inc.	‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	11266719	March 8, 2022
	‌ US Patent 9919032 Method for administering a sustained release formulation	Patent 9919032 was granted and assigned to Phasebio Pharmaceuticals, Inc. on March, 2018 by the United States Patent and Trademark Office.	‌ Phasebio Pharmaceuticals, Inc.	‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	9919032	March 20, 2018
	‌ US Patent 9029505 Modified vasoactive intestinal peptides	Patent 9029505 was granted and assigned to Phasebio Pharmaceuticals, Inc. on May, 2015 by the United States Patent and Trademark Office.		‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	9029505	May 12, 2015
	‌ US Patent 9561262 Use of modified vasoactive intestinal peptides in the treatment of hypertension	Patent 9561262 was granted and assigned to Phasebio Pharmaceuticals, Inc. on February, 2017 by the United States Patent and Trademark Office.		‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	9561262	February 7, 2017
	‌ US Patent 10688156 Methods and compositions for treating muscle disease and disorders		‌ Phasebio Pharmaceuticals, Inc.	‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	10688156	June 23, 2020
	‌ US Patent 11052132 Methods and compositions for treating cystic fibrosis	Patent 11052132 was granted and assigned to Phasebio Pharmaceuticals, Inc. on July, 2021 by the United States Patent and Trademark Office.	‌ Phasebio Pharmaceuticals, Inc.	‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	11052132	July 6, 2021
	‌ US Patent 10940182 Use of modified vasoactive intestinal peptides in the treatment of hypertension	Patent 10940182 was granted and assigned to Phasebio Pharmaceuticals, Inc. on March, 2021 by the United States Patent and Trademark Office.	‌ Phasebio Pharmaceuticals, Inc.	‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	10940182	March 9, 2021
	‌ US Patent 10722590 ELP fusion proteins for controlled and sustained release	Patent 10722590 was granted and assigned to Phasebio Pharmaceuticals, Inc. on July, 2020 by the United States Patent and Trademark Office.	‌ Phasebio Pharmaceuticals, Inc.	‌ Phasebio Pharmaceuticals, Inc.		United States Patent and Trademark Office	10722590	July 28, 2020

10 results

0 selected

10 results

0 selected